Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Key Inclusion Criteria:

1. Medical history of type 2 diabetes and receiving medical therapy or lifestyleinterventions for glucose management

2. Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening

3. eGFR 30 to 90 mL/min/1.73 m^2 using 2021 Chronic Kidney Disease-EpidemiologyCollaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening

4. Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g atscreening

Key Exclusion Criteria:

1. Known medical history or clinical evidence indicative of non-diabetic renal disease

2. Renal disease that required treatment with systemic immunosuppressive therapy, or ahistory of dialysis or renal transplant

3. Medically unstable as assessed by the investigator

4. Hospitalization (ie, >24 hours) within 30 days of the screening visit

NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply